Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.
Scott T. Tagawa, MD, MS, professor of Medicine and Urology, and medical director of Genitourinary Oncology Research Program at Weill Cornell Medicine, discusses a phase I dose-escalation study of actinium-225 (225Ac-J591) in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor (NCT03276572).
The investigators of this trial did not reach a maximum tolerated dose, according to Tagawa. The study had 7 cohorts, and in 6 out of the 7, 1 patient had grade 4 anemia and thrombocytopenia. In the next cohort, none of the 6 patients had dose-limiting toxicities (DLTs), which were defined as grade 4 hematologic toxicity or grade 3/4 non-hematologic toxicity. Since none of these patients had DLTs, the study authors concluded that there was no maximum tolerated dose defined for this therapy. That cohorts received 93.3 KBq/kg which is now the recommended phase II dose.
Some adverse events that were not DLTs occurred with this therapy, such as grade 3 anemia in 1 patient and the rest were grade 1 and 2 toxicities.
<< View more resources and information regarding prostate cancer
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More